Skip to main content
OpenTrials
Completed

NCT Number: NCT04119557

A Study of LY3471851 in Participants With Psoriasis

The main purpose of this study is to learn more about the safety of LY3471851 when given by injection just under the skin to participants with psoriasis. The study will last up to 48 weeks and may include up to 23 visits to the study center.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Psoriasis Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Arkansas Research Trials, LLC, North Little Rock, Arkansas, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Have a confirmed diagnosis of psoriasis for at least 6 months
  • Have active psoriasis plaques according to study- specific criteria
  • Be willing and able to undergo skin biopsies

Exclusion criteria

  • Have received certain topical medications for psoriasis within 14 days prior to baseline
  • Have received certain systemic medications for psoriasis within 4 weeks prior to baseline
  • Have received LY3471851 previously

Treatment and study plan

Placebo

Drug

Administered SC

LY3471851

Drug

Administered SC

Other names: NKTR-358

Primary outcomes

  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    Time frame: Baseline through Study Completion (up to Week 48)

    A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

Secondary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3471851

    Time frame: Postdose on Day 1 through Day 14

    PK: AUC of LY3471851

  2. PK: Trough Concentrations (Ctrough) of LY3471851

    Time frame: Week 12

    PK: Ctrough of LY3471851

  3. PK: Maximum Concentration (Cmax) of LY3471851

    Time frame: Postdose on Day 1 through Day 14

    PK: Cmax of LY3471851

Sponsors and collaborators

Lead sponsor

Nektar Therapeutics

Industry

Collaborators

  • Eli Lilly and Company

Registry information

Official study title

A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
Oct 8, 2019
Registry last updated
Feb 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.